KR20110004603A - Cauliflower extract for treating or preventing menopausal diseases, preventing skin aging, or improving skin wrinkles - Google Patents
Cauliflower extract for treating or preventing menopausal diseases, preventing skin aging, or improving skin wrinkles Download PDFInfo
- Publication number
- KR20110004603A KR20110004603A KR1020090062112A KR20090062112A KR20110004603A KR 20110004603 A KR20110004603 A KR 20110004603A KR 1020090062112 A KR1020090062112 A KR 1020090062112A KR 20090062112 A KR20090062112 A KR 20090062112A KR 20110004603 A KR20110004603 A KR 20110004603A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- active ingredient
- painting
- estrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 110
- 208000017657 Menopausal disease Diseases 0.000 title claims abstract description 22
- 230000037303 wrinkles Effects 0.000 title claims abstract description 16
- 230000009759 skin aging Effects 0.000 title claims abstract description 12
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 title 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 80
- 239000000262 estrogen Substances 0.000 claims abstract description 47
- 229940011871 estrogen Drugs 0.000 claims abstract description 47
- 238000010422 painting Methods 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 41
- 239000004480 active ingredient Substances 0.000 claims abstract description 35
- 102000029816 Collagenase Human genes 0.000 claims abstract description 26
- 108060005980 Collagenase Proteins 0.000 claims abstract description 26
- 230000028327 secretion Effects 0.000 claims abstract description 26
- 229960002424 collagenase Drugs 0.000 claims abstract description 24
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 230000006872 improvement Effects 0.000 claims abstract description 6
- 208000033830 Hot Flashes Diseases 0.000 claims abstract description 4
- 206010060800 Hot flush Diseases 0.000 claims abstract description 4
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 235000013399 edible fruits Nutrition 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 11
- 235000013376 functional food Nutrition 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 241000218645 Cedrus Species 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract description 16
- 229960005309 estradiol Drugs 0.000 abstract description 15
- 229930182833 estradiol Natural products 0.000 abstract description 14
- 102000008186 Collagen Human genes 0.000 abstract description 9
- 108010035532 Collagen Proteins 0.000 abstract description 9
- 229920001436 collagen Polymers 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 239000003075 phytoestrogen Substances 0.000 abstract description 7
- 230000009245 menopause Effects 0.000 abstract description 6
- 230000003712 anti-aging effect Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 206010017711 Gangrene Diseases 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 22
- 239000000796 flavoring agent Substances 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 241000208343 Panax Species 0.000 description 8
- 235000002791 Panax Nutrition 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940077731 carbohydrate nutrients Drugs 0.000 description 5
- 239000004744 fabric Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 241000209020 Cornus Species 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- -1 pH adjusters Substances 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010027304 Menopausal symptoms Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000237502 Ostreidae Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000020636 oyster Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 239000001512 FEMA 4601 Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000046101 Sophora japonica Species 0.000 description 2
- 235000010586 Sophora japonica Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940027779 persimmon extract Drugs 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019203 rebaudioside A Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 235000013555 soy sauce Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- SYZJDGAOLGLIDX-UHFFFAOYSA-N 1-hydroxyazocane Chemical compound ON1CCCCCCC1 SYZJDGAOLGLIDX-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 208000005736 Nervous System Malformations Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 244000288157 Passiflora edulis Species 0.000 description 1
- 235000000370 Passiflora edulis Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241001122315 Polites Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 235000013999 Prunus japonica Nutrition 0.000 description 1
- 241000392950 Prunus japonica Species 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003687 estradiol congener Substances 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000005813 organ abnormality Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000021264 seasoned food Nutrition 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 에스트로겐 분비를 촉진하고, 콜라게네이즈 활성을 저해하는 회화나무 추출물을 유효성분으로 포함하는 조성물에 관한 것으로서, 보다 상세하게는 회화나무 추출물을 유효성분으로 포함하고, 에스트로겐 분비를 촉진하여 폐경기 질환을 치료 또는 예방하는 조성물, 회화나무 추출물을 유효성분으로 포함하고, 콜라게네이즈 활성을 저해하는 피부 노화 방지용 화장료 조성물, 및 회화나무 추출물을 유효성분으로 포함하고, 콜라게네이즈 활성을 저해하는 주름 개선용 화장료 조성물에 관한 것이다.The present invention relates to a composition comprising a painting tree extract that promotes estrogen secretion and inhibits collagenase activity as an active ingredient, and more specifically, includes a painting tree extract as an active ingredient and promotes estrogen secretion by menopause. A composition for treating or preventing a disease, a cosmetic composition for preventing skin aging that contains collagen extract as an active ingredient, and a collagen extract for inhibiting collagenase activity, and a wrinkle that contains collagena extract as an active ingredient, and inhibits collagenase activity It relates to a cosmetic composition for improvement.
본 발명의 회화나무 추출물을 유효 성분으로 포함하는 조성물은 에스트로겐 분비를 촉진하여, 종래의 호르몬 대체 요법에 사용되는 에스트로겐 대체제 중 에스트라디올 보다 효과가 뛰어나며, 동시에 콜라게네이즈 활성을 저해하여, 폐경기 질환을 치료 또는 예방할 수 있음과 동시에, 피부 노화 방지 또는 피부 주름 개선용으로도 사용될 수 있다. The composition comprising the extract of the present invention as an active ingredient promotes estrogen secretion, is more effective than estradiol among the estrogen replacement agents used in conventional hormone replacement therapy, and at the same time inhibits collagenase activity, thereby preventing menopausal diseases At the same time it can be treated or prevented, it can also be used for preventing skin aging or improving skin wrinkles.
따라서, 본 발명의 회화나무 추출물은 에스트로겐의 분비가 부족한 폐경기 이후 여성들의 다양한 증상에 적용할 수 있으며, 동시에 피부 개선 효과도 나타나 폐경기 이후 증상의 개선, 예방, 또는 치료에 널리 사용될 수 있다.Therefore, the extract of the present invention can be applied to various symptoms of women after menopause lacking the secretion of estrogen, and at the same time, the skin improvement effect can also be used to improve, prevent, or treat the symptoms after menopause.
회화나무, 괴각, 에스트로겐, 폐경기, 갱년기, 식물성 에스트로겐, 골다공증, 안면 홍조, 피부 노화 방지, 피부 주름 개선 Painting tree, gangrene, estrogen, menopause, menopause, phytoestrogens, osteoporosis, hot flashes, anti-aging skin, wrinkle improvement
Description
본 발명은 폐경기 질환의 치료 또는 예방, 피부 노화 방지, 또는 피부 주름 개선용으로 사용될 수 있는 회화나무 추출물을 유효 성분으로 포함하는 조성물에 관한 것이다. The present invention relates to a composition comprising, as an active ingredient, a painting tree extract that can be used for the treatment or prevention of menopausal diseases, to prevent skin aging, or to improve skin wrinkles.
에스트로겐(estrogen)은 체내에서 콜레스테롤로부터 합성되고 난소, 부신피질, 고환, 태아 태반계에서 분비되는 여성 호르몬으로 에스트라디올(estradiol), 에스트론(estrone), 에스트리올(estriol) 등을 총칭하여, 이중 에스트라디올이 가장 유용한 것으로 알려져 있다.Estrogen is a female hormone synthesized from cholesterol in the body and secreted by the ovaries, adrenal cortex, testes, and fetal placenta, estradiol, estrone, and estriol. Estradiol is known to be the most useful.
이러한 에스트로겐은 뼈 조직뿐만 아니라 심장, 혈관, 중추 신경계 등 다양한 조직의 기능을 보호하는 작용이 탁월하고, 여성의 2차 성징을 유지시키는 기능을 수행하며, 배자(胚子)발생, 세포 성장, 생식 등에 있어서도 중요한 역할을 한다. 또한 동물의 발정기, 영장류에서는 월경 시에 자궁 내막의 증식을 촉진하는 역할을 수행하기도 한다.These estrogens are excellent in protecting the functions of various tissues such as the heart, blood vessels, and central nervous system, as well as bone tissues, and maintain the secondary sexual characteristics of women. Embryonic development, cell growth, reproduction, etc. Also plays an important role. In estrus and primates, animals also play a role in promoting the growth of the endometrium during menstruation.
따라서, 여성이 폐경기가 되어 에스트로겐 분비가 감소하면, 안면 홍조, 발한 등의 신경 혈관계 이상, 골다공증 등의 운동 기관계 이상, 우울증 등의 정신 신경 계통 이상, 피부 조직의 변화, 탈모 등의 여러 질환이 발생할 수 있다.Therefore, when a woman is menopausal and estrogen secretion decreases, various diseases such as facial flushing, neurovascular system such as sweating, motor organ system such as osteoporosis, mental nervous system system such as depression, skin tissue change, and hair loss may occur. Can be.
이에 상기한 에스트로겐을 투여함으로써 폐경기 이후 여성의 질병을 예방하는 방법이 널리 사용되고 있다. 그러나 에스트로겐 제제를 장기간 복용하는 경우, 암이나 담낭 질환 유발 등 그 부작용이 심각하다는 문제가 있어 왔다. 따라서 현재 이와 같은 갱년기 질환 등의 치료 방법으로서 대체 호르몬 투여 방법을 사용하고 있고, 그 중 식물성 에스트로겐(phytoestrogen)의 역할이 비중 있게 다루어지고 있다.Therefore, the method of preventing the disease of women after menopause by administering the above-mentioned estrogen is widely used. However, when taking estrogen preparations for a long time, there have been problems of serious side effects such as cancer and gallbladder disease. Therefore, the current hormone replacement method is used as a treatment method for such menopausal diseases, and among them, the role of phytoestrogen is dealt heavily.
상기 식물성 에스트로겐은 에스트로겐 생성 효과를 나타내는 에스트로겐 모방 물질로서 세포 내에 있는 에스트로겐 수용체(estrogen receptor)와 결합하여 DNA의 특정 염기 서열 즉, 에스트로겐 반응 인자(Estrogen Responsive Element)를 인식하여 결합한다. 이러한 유전자와 단백질의 결합은 특정 단백질의 전사를 증대시키며, 결국 에스트로겐 유사물질에 의한 세포 반응을 유도하는 것으로 알려져 있다. (Gaido KW et al. Endocrinology 1999 140(12):5746-53; Gronen S et al., Environ.Health Perspect. 1999 107(5):385-90)The phytoestrogens are estrogen mimetics that exhibit estrogen-generating effects and bind to estrogen receptors in cells to recognize and bind to specific nucleotide sequences, ie, estrogen responsive elements, of DNA. The combination of these genes and proteins increases the transcription of certain proteins, and is known to induce cellular responses by estrogen analogs. (Gaido KW et al. Endocrinology 1999 140 (12): 5746-53; Gronen S et al., Environ. Health Perspect. 1999 107 (5): 385-90)
이에 에스트로겐 대체 효과를 통해, 암세포 억제, 갱년기 장애 증상 완화, 노화 방지 등의 효과를 가져오면서도, 식물로부터 분리되어 보다 안전한 식물성 에스트로겐에 대한 발굴과 그 활용이 예의 요구된다.The estrogen replacement effect, while having the effects of inhibiting cancer cells, relieving menopausal disorder symptoms, anti-aging, etc., it is polite to find and use safer phytoestrogens that are separated from plants.
본 발명의 발명자들은 에스트로겐 대체 제제로서 식물성 에스트로겐을 포함 하는 추출물에 관해 연구를 거듭 하던 중, 본 발명을 완성하게 되었다.The inventors of the present invention have completed the present invention while repeatedly researching an extract containing phytoestrogens as an estrogen replacement agent.
이에, 본 발명은 에스트로겐 분비를 촉진하고, 콜라게네이즈 활성을 저해하는 회화나무 추출물을 유효성분으로 포함하는 조성물을 제공한다.Accordingly, the present invention provides a composition comprising a painting extract as an active ingredient to promote estrogen secretion, inhibiting collagenase activity.
상기와 같은 목적을 달성하기 위하여, 본 발명은 회화나무 추출물을 유효성분으로 포함하고, 에스트로겐 분비를 촉진하는 폐경기 질환의 치료 또는 예방 조성물을 제공한다.In order to achieve the above object, the present invention includes a painting tree extract as an active ingredient, and provides a treatment or prevention composition for menopausal diseases promoting estrogen secretion.
또한, 본 발명은 회화나무 추출물을 유효성분으로 포함하고, 콜라게네이즈 활성을 저해하는 피부 노화 방지용 화장료 조성물 및 피부 주름 개선용 화장료 조성물을 제공한다.In another aspect, the present invention comprises a painting extract as an active ingredient, and provides a cosmetic composition for preventing skin aging and a cosmetic composition for improving skin wrinkles that inhibit collagenase activity.
본 발명은 일 구현예에 따라, 회화나무 추출물을 유효성분으로 포함하고, 에스트로겐 분비를 촉진하는 폐경기 질환의 치료 또는 예방 조성물을 제공한다.The present invention provides a therapeutic or prophylactic composition for postmenopausal disease, comprising a cedar extract as an active ingredient and promoting estrogen secretion.
상기 회화나무는 학명 Sophora japonica로, 콩과에 속하며, 높이 25m 안 팎으로, 한국, 일본, 중국 등지에 분포한다. 가지가 퍼지고 작은 가지는 녹색이며 자르면 냄새가 나는 것이 특징이며, 잎은 어긋나고 1회 깃꼴겹잎이다. 작은잎은 1 내지 17개씩이고, 달걀 모양 또는 달걀 모양의 타원형이며, 뒷면에는 작은 잎자루와 더불어 누운털이 있으며, 꽃은 8월에 연한 황색으로 피고 원추꽃차례로 달린다. 꼬투리는 길이 5 내지 8cm이고 종자가 들어있는 사이가 잘록하게 들어가면 밑으로 처 진 형태를 갖는다.The painting tree is a scientific name Sophora japonica, belongs to the legumes, 25m in height and around, and is distributed in Korea, Japan, China and the like. Branches are spread and small branches are green and have a smell when they are cut. Leaves are alternate and single pinnate leaves. Small leaves 1 to 17 each, egg-shaped or oval-shaped oval, with petioles on the back, with lie down hairs, flowers bloom in light yellow in August and run in conical inflorescences. The pod has a length of 5 to 8 cm and has a drooping shape when the seeds are inserted in a narrow shape.
상기와 같은 회화나무의 꽃봉오리를 괴화 또는 괴미라고 하며 열매를 괴실 또는 괴각이라 하는데, 모두 약용으로 한다. 열매는 협과로 원기둥 또는 염주 모양이며, 과실은 가지 및 나무껍질과 더불어 치질치료에 쓰이기도 하며, 정원수나 목재는 가구재로 이용되기도 한다. 한편, 괴화의 알려진 용도로는 동맥경화 및 고협압의 치료 또는 예방이며, 맥주와 종이를 황색으로 만드는데 쓰이기도 한다.The buds of the painting tree as described above are called Goehwa or Goemi, and the fruit is called Goesil or Goke. Fruits are citrus, columnar or beads. Fruits are used to treat hemorrhoids, along with branches and bark. Garden trees and wood are also used as furniture. On the other hand, the known use of hardening is the treatment or prevention of atherosclerosis and high stenosis, and it is also used to make beer and paper yellow.
본 발명의 발명자들은 에스트로겐 대체제로 식물성 에스트로겐에 대해 연구를 거듭하던 중, 상기와 같은 회화나무, 특히 회화나무의 열매가 에스트로겐 분비를 촉진하고, 콜라게네이즈 합성을 저해하는 것을 발견하고 본 발명을 완성하였다. 특히, 실험결과 에스트로겐 중 가장 효능이 뛰어난 것으로 알려진 에스트라디올보다 본원의 회화나무 열매 추출물의 에스트로겐 분비 활성이 더욱 좋은 것을 알아내어 본 발명을 완성하였다. 또한, 회화나무 추출물을 유효성분으로 포함하는 조성물의 경우, 에스트로겐 대체 효과를 통해, 암세포 억제, 갱년기 장애 증상 완화, 노화 방지 등의 효과를 가져오면서도, 식물로부터 분리되어 보다 안전한 식물성 에스트로겐으로서 안심하고 사용될 수 있어, 폐경기 질환의 치료 또는 예방 조성물로 널리 사용될 수 있을 것으로 기대된다.The inventors of the present invention, while repeatedly researching phytoestrogens as an estrogen replacement agent, found that the fruit of the above-mentioned picture tree, especially the picture tree, promotes estrogen secretion and inhibits collagenase synthesis, thus completing the present invention. It was. In particular, the experimental results have been found that the estrogen secretion activity of the painting tree fruit extract of the present application is better than the estradiol known to be the most effective of the estrogens to complete the present invention. In addition, in the case of the composition containing the extract as an active ingredient, the effect of replacing estrogen, while suppressing cancer cells, alleviating symptoms of menopausal disorders, and preventing aging, while being separated from the plant, it is safer as a safe phytoestrogens. It is anticipated that it can be used widely, as a therapeutic or prophylactic composition for menopausal diseases.
이 때, 상기 회화나무 추출물은 회화나무로부터 유래된 것이면, 그 구성의 한정이 없이 추출하여 사용할 수 있으나, 바람직하게는 열매 추출물인 괴각 추출물이 바람직하다. 여러 가지 회화나무 추출물 중 열매 추출물인 괴각 추출물의 에스트로겐 분비 활성 및 콜라게네이즈 활성 저해 효능이 가장 뛰어난 것으로 나타났 다.At this time, if the painting tree extract is derived from the painting tree, it can be used to extract without limitation of the constitution, Preferably, the lump extract which is a fruit extract is preferable. Among the various extracts from the extract, the fruit extract, the gangwi extract, was found to be the most effective in inhibiting estrogen secretion and collagenase activity.
한편, 상기와 같은 추출물의 준비를 위해 사용되는 추출 용매는 그 구성의 한정이 없이 선택될 수 있다. 구체적으로, 물, 탄소수 1 내지 5의 알코올, 에틸아세테이트, 헥산, 디클로로메탄, 아세폰, 클로로포름, 메틸렌 클로라이드 및 이들의 혼합물로 이루어진 군으로부터 1종 이상 선택된 추출용매로 추출할 수 있다. 이 때, 상기 탄소수 1 내지 5의 알코올은 그 구성의 한정이 없이 선택하여 사용할 수 있으나, 바람직하게는 에탄올을 사용할 수 있고, 더욱 바람직하게는 에탄올 75 내지 85%(v/v)를 사용하여 추출할 수 있다. 상기와 같은 에탄올 75 내지 85%(v/v)를 사용하여 추출된 회화나무 추출물의 에스트로겐 분비 활성은 후술할 실험예들의 결과로 기재된 바와 같이, 에스트라디올보다 뛰어난 것으로 확인되었다. 가장 바람직하게는 에탄올 80%(v/v)를 사용하여 추출할 수 있다. On the other hand, the extraction solvent used for the preparation of the extract as described above may be selected without limiting its configuration. Specifically, it may be extracted with at least one extraction solvent selected from the group consisting of water, alcohol having 1 to 5 carbon atoms, ethyl acetate, hexane, dichloromethane, acefon, chloroform, methylene chloride, and mixtures thereof. At this time, the alcohol having 1 to 5 carbon atoms can be selected and used without limitation of the composition, preferably ethanol can be used, more preferably extracted using 75 to 85% (v / v) of ethanol can do. The estrogen secretion activity of the cedar extract extracted using 75 to 85% (v / v) of ethanol as described above was confirmed to be superior to estradiol, as described in the results of the experimental examples described below. Most preferably it can be extracted using 80% ethanol (v / v).
한편, 상기와 같은 회화나무 추출물은 통상의 식물 추출물의 제조방법에 따라 제조된 것일 수 있다. 바람직하게는 상기 회화나무의 꽃, 열매, 나무 껍질, 뿌리 또는 이들 중 1종 이상을 분쇄한 후에 잔사를 제거한 다음, 이에 상기 분쇄물의 중량비로 3 내지 7배에 상응하는 추출 용매를 첨가하고, 상온에서 추출할 수 있다.On the other hand, the painting tree extract as described above may be prepared according to the conventional method for producing a plant extract. Preferably the flower, fruit, bark, roots or roots of the painting tree is pulverized, and then the residue is removed. Then, an extraction solvent corresponding to 3 to 7 times the weight ratio of the pulverized product is added thereto, and room temperature. Can be extracted from
한편, 추출 시간은 한정이 없으나, 바람직하게는 10 내지 24시간 추출하는 것이 바람직하다. 10시간 미만으로 추출하는 경우, 추출되는 유효 성분의 함량이 적으며, 24시간을 초과하는 경우, 추출 시간이 길어짐에 따른 효능의 증가가 미미하여 생산성 측면에서 바람직하지 않다.On the other hand, the extraction time is not limited, but preferably 10 to 24 hours extraction. If the extraction time is less than 10 hours, the content of the active ingredient to be extracted is small, if more than 24 hours, the increase in efficacy as the extraction time is long is not preferable in terms of productivity.
상기와 같은 방법으로 추출한 회화나무 추출액은 여과포 등으로 여과한 후, 여액을 원심분리시켜 침전물을 제거시킨 다음, 감압 농축 또는 농축 한 후, 동결 건조할 수 있다. 더욱 바람직하게는 상기 조성물은 회화나무 열매를 75 내지 85%(v/v)의 에탄올로 상온에서 10 내지 24시간 추출한 것일 수 있다. 가장 바람직하게는 상기 조성물은 회화나무 열매를 80%(v/v)의 에탄올로 상온에서 10 내지 24시간 추출한 것일 수 있다.The picture extract extracted in the above manner is filtered through a filter cloth or the like, the filtrate is centrifuged to remove the precipitate, and then concentrated under reduced pressure or concentrated, and then freeze-dried. More preferably, the composition may be extracted from the painting tree fruit with 75 to 85% (v / v) of ethanol at room temperature for 10 to 24 hours. Most preferably, the composition may be extracted from the painting tree fruit with 80% (v / v) of ethanol at room temperature for 10 to 24 hours.
상기와 같은 조건에서 추출한 회화나무 열매 추출물의 에스트로겐 분비 촉진 활성 및 콜라게네이즈 활성 저해 효과가 뛰어남을 관찰하였다.The effect of inhibiting estrogen secretion promoting activity and collagenase activity of the extract of the Prunus japonica extract extracted under the above conditions was observed.
한편, 본 명세서에서 정의하는 '폐경기 질환' 이란 폐경기 여성들의 에스트로겐 분비 감소와 관련되어 겪게 되는 질환을 통칭하는 것으로서, 폐경기 이후에 나타나는 동맥경화성 심혈관병 등의 심혈관 질환, 안면홍조, 발한 등과 같은 신경혈관계 이상, 골다공증 등과 같은 운동 기관계 이상, 우울증 등과 같은 정신 신경 계통 이상, 피부 조직의 변화 및 탈모증 등을 포함한다. Meanwhile, the term "menopausal disease" as used herein refers to a disease that is associated with decreased estrogen secretion in postmenopausal women, and cardiovascular diseases such as atherosclerotic cardiovascular disease, postmenopausal cardiac disease, hot flashes, and sweating. Abnormalities, motor organ abnormalities such as osteoporosis, mental nervous system abnormalities such as depression, skin tissue changes and alopecia and the like.
한편, 상술한 구현예의 폐경기 질환의 치료 또는 예방 조성물 중 유효성분인 회화나무 추출물의 함량은 한정은 없으나, 바람직하게 0.001 내지 30중량% 일 수 있다. 유효 성분인 회화나무 추출물의 함량이 0.001중량% 미만인 경우에는, 에스트로겐 분비 촉진 효과 또는 콜라게네이즈 활성 저해 효과가 미미하며, 30중량%를 초과하는 경우에는 함량 증가에 따른 활성 증가 효과가 미미하여, 경제적이지 못하다.On the other hand, the content of the painting tree extract as an active ingredient in the treatment or prevention composition for menopausal diseases of the above-described embodiment is not limited, but may preferably be 0.001 to 30% by weight. When the content of the extract of the active tree is less than 0.001% by weight, the effect of promoting estrogen secretion or inhibiting collagenase activity is insignificant, and when it exceeds 30% by weight, the effect of increasing the activity by increasing the content is insignificant. Not
본 발명은 구현예에 따라 상기 회화나무 추출물을 유효성분으로 포함하고, 에스트로겐 분비 촉진하는 폐경기 질환의 치료 또는 예방 조성물을 포함하는 의약 품을 제공한다. 상기 회화나무 추출물을 유효성분으로 포함하는 의약품은 그 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.The present invention provides a medicament comprising the extract according to the embodiment as an active ingredient, comprising a therapeutic or prophylactic composition for menopausal diseases promoting estrogen secretion. Medicines containing the painting extract as an active ingredient may further comprise a suitable carrier, excipients and diluents commonly used in the preparation thereof.
본 발명의 회화나무 추출물을 유효성분으로 포함하는 의약품에 포함될 수 있는 담체, 부형제 및 희석제로는 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Carriers, excipients and diluents that may be included in a pharmaceutical product containing the extract of the present invention as an active ingredient include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin , Calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 회화나무 추출물을 유효성분으로 포함하는 의약품은 각각 통상의 방법에 따라 산제, 과립제, 정제, 현탁제, 에멀젼, 시럽 등의 경구형 제형물로 사용될 수 있다.Medicines containing the extract of the present invention as an active ingredient may be used in oral formulations, such as powders, granules, tablets, suspensions, emulsions, syrups, etc. according to conventional methods.
상기 경구형 제형물은 경구 투여를 위한 고형제제와 액상제제를 포함하는 의미이며, 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함될 수 있으며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럼제 등이 해당되는데, 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러가지 부형제 예를 들면, 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.The oral formulation is meant to include a solid preparation and a liquid preparation for oral administration, the solid preparation for oral administration may include tablets, pills, powders, granules, capsules, etc., such solid preparation is the extract At least one excipient, for example, may be prepared by mixing starch, calcium carbonate, sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solvents, emulsions, and serums.In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have.
본 발명의 회화나무 추출물을 함유하는 조성물의 바람직한 투여량은 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 바람직하게는 본 발명의 회화나무 추출물을 유효성분으로 함유하는 의약품은 회화나무 추출물의 양을 기준으로 1일 0.0001 내지 100mg/kg으로, 보다 효과적이기 위해서는 0.01 내지 10mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량과 투여횟수는 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the compositions containing the cedar extract of the present invention vary depending on the condition and body weight, extent of disease, drug form, route of administration and duration, and may be appropriately selected by those skilled in the art. Preferably, the medicine containing the painting tree extract of the present invention as an active ingredient is 0.0001 to 100mg / kg per day based on the amount of the painting tree extract, in order to be more effective it is preferably administered at 0.01 to 10mg / kg. Administration may be administered once a day or may be divided several times. The dosage and frequency of administration are not intended to limit the scope of the invention in any aspect.
본 발명의 다른 구현예에 따라, 회화나무 추출물을 유효성분으로 포함하는 폐경기 질환의 개선 또는 예방용 건강 기능성 식품을 제공한다. 본 명세서에서 '건강 기능성 식품' 이라 함은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미한다.According to another embodiment of the present invention, there is provided a functional food for the improvement or prevention of menopausal diseases comprising a painting extract as an active ingredient. As used herein, the term "health functional food" means a natural product or a processed product containing one or more nutrients, and preferably means a state in which it can be directly eaten through a certain processing process.
본 발명의 회화나무 추출물을 첨가할 수 있는 건강 기능성 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예, 과실,채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면 스프 등)을 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다.Examples of health functional foods to which the painting extract of the present invention can be added include various foods, beverages, gums, teas, vitamin complexes, and the like. In addition, the food in the present invention includes special nutritional products (e.g., prepared oils, infants, baby food, etc.), processed meat products, fish products, tofu, jelly, noodles (e.g. ramen, noodles, etc.), health supplements, seasoned foods ( For example, soy sauce, miso, red pepper paste, mixed soy sauce), sauces, confectionery (e.g. snacks), dairy products (e.g. fermented milk, cheese, etc.), other processed foods, kimchi, pickles (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruits, vegetable drinks, soy milk, fermented beverages, and the like, and natural seasonings (eg, ramen soup). The food, beverage or food additives may be prepared by a conventional manufacturing method.
본 명세서에서, 기능성 식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다. 상기 기능성 식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 기능성 식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.In the present specification, the functional food is a biological defense rhythm control, disease prevention and the like having a food group or food composition that has added value to the food by using physical, biochemical, biotechnological techniques, etc. to function and express the function of the food for a specific purpose. It means a food that is designed and processed to fully express the gymnastics function on recovery. The functional food may include food acceptable food additives, and may further include appropriate carriers, excipients and diluents commonly used in the manufacture of functional foods.
본 명세서에서, 음료란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며 기능성 음료를 포함하는 의도이다. 상기 음료는 지시된 비율로 필수 성분으로서 상기 회화나무 추출물을 유효성분으로 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기의 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖ 당 일반적으로 약 1 내지 20g, 바람직하게는 5 내지 12g일 수 있다. 그밖에 본 발명의 조성물은 천연 과일 주스, 과일 쥬스 음료, 야채 음료의 제조를 위한 과육을 추가로 함유할 수 있다.In the present specification, the beverage is a generic term for drinking to quench thirst or to enjoy a taste and is intended to include a functional beverage. The beverage is not particularly limited to other ingredients other than including the painting tree extract as an active ingredient in the indicated ratio as an active ingredient, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. . Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and Sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate may generally be about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention. It may further contain a pulp for.
상기 외에 본 발명의 건강 기능성 식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분을 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지 않지만, 본 발명의 회화나무 추출물 100 중량부 당 0 내지 20 중량부 범위에서 선택될 수 있다.In addition to the above, the health functional food of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid And salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. These components can be used independently or in combination. The proportion of such additives is not so critical, but may be selected in the range of 0 to 20 parts by weight per 100 parts by weight of the extract of the present invention.
본 명세서에서 기능성 음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미한다.In the present specification, the functional beverage refers to a biological defense rhythm control, disease prevention, and the like having a beverage group or a beverage composition which has added value to the beverage by using physical, biochemical, or biotechnological techniques to act and express the function of the beverage to a specific purpose. Means a beverage that is designed and processed to fully express the gymnastics function related to recovery.
상기 기능성음료는 지시된 비율로 필수 성분으로서 본 발명의 회화나무 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등) 를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖ 당 일반적으로 약 1 내지 20 g, 바람직하게는 5 내지 12 g이다.The functional beverage is not particularly limited to other ingredients except the painting tree extract of the present invention as an essential ingredient at the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and other disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like, and xylitol Sugar alcohols such as sorbitol and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention.
또한, 폐경기 질환의 개선 또는 예방을 목적으로 하는 건강 기능성 식품 에 있어서, 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 포함할 수 있으며, 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1g의 비율로 포함할 수 있다.In addition, in the health functional food for the purpose of improving or preventing menopausal diseases, the amount of the extract may include 0.01 to 15% by weight of the total food weight, the beverage composition is 0.02 to 5 g based on 100 ml, Preferably it may be included in a ratio of 0.3 to 1g.
본 발명은 다른 구현예에 따라, 회화나무 추출물을 유효성분으로 포함하고, 콜라게네이즈 활성을 저해하는 피부 노화 방지용 화장료 조성물을 제공한다.According to another embodiment, the present invention provides a cosmetic composition for preventing skin aging, which comprises a painting extract as an active ingredient and inhibits collagenase activity.
또한, 본 발명은 또 다른 구현예에 따라, 회화나무 추출물을 유효 성분으로 포함하고, 콜라게네이즈 활성을 저해하는 피부 주름 개선용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for improving skin wrinkles, which comprises a painting tree extract as an active ingredient and inhibits collagenase activity according to another embodiment.
상기와 같은 구현예들에 따른 피부 노화 방지용 또는 피부 주름 개선용 화장료 조성물은 회화나무 추출물을 유효성분으로 포함하여, 피부의 주요한 구성 성분인 콜라겐의 분해 효소인 콜라게네이즈의 활성을 저해하여 피부의 노화 방지 또는 피부 주름 개선에 유용하게 사용될 수 있다.The cosmetic composition for preventing skin aging or improving skin wrinkles according to the embodiments as described above comprises a painting extract as an active ingredient, inhibiting the activity of collagenase, a degradation enzyme of collagen, which is a major component of the skin, It can be usefully used for anti-aging or for improving skin wrinkles.
회화나무 추출물을 유효성분으로 포함하고, 에스트로겐 분비를 촉진하는 폐경기 질환의 치료 또는 예방 조성물에 관한 상술한 구현예에서 언급한 바와 같이, 피부 노화 방지용 화장료 조성물 또는 피부 주름 개선용 화장료 조성물에 있어서도, 상기 회화나무 추출물은 회회나무 열매의 추출물인 것이 바람직하다.As mentioned in the above-described embodiment of the treatment or preventive composition for treating menopausal diseases, which comprises the extract as an active ingredient and promotes estrogen secretion, in the cosmetic composition for preventing skin aging or the cosmetic composition for improving skin wrinkles, The tree extract is preferably an extract of the ash tree fruit.
상기와 같은 회화나무 추출물을 유효 성분으로 포함하는 피부 노화 방지용 또는 피부 주름 개선용 조성물은 상술한 폐경기 질환의 치료 또는 예방 조성물에서 언급한 방법에 따라 준비될 수 있다.A composition for preventing skin aging or for improving skin wrinkles, which comprises the above picture extract as an active ingredient, may be prepared according to the method mentioned in the treatment or prevention composition for menopausal diseases described above.
바람직하게는 회화나무 추출물은 물, 탄소수 1 내지 5의 알코올, 에틸아세테이트, 헥산, 디클로로메탄, 아세폰, 클로로포름, 메틸렌 클로라이드 및 이들의 혼합물로 이루어진 군으로부터 1종 이상 선택된 추출용매로 추출할 수 있으며, 더욱 바람직하게는 에타올을 추출 용매로 하고, 가장 바람직하게는 에탄올은 75내지 85%(v/v) 에탄올을 추출 용매로 사용할 수 있다.Preferably, the extract may be extracted with at least one extractant selected from the group consisting of water, alcohol having 1 to 5 carbon atoms, ethyl acetate, hexane, dichloromethane, acefon, chloroform, methylene chloride, and mixtures thereof. More preferably, ethanol may be used as the extraction solvent, and most preferably ethanol may use 75 to 85% (v / v) ethanol as the extraction solvent.
피부 노화 방지 또는 피부 주름 개선용 화장료 조성물로는 회화나무 열매를 75내지 85%(v/v)의 에탄올의 용매로 상온에서 10 내지 24시간 추출한 조성물일 수 있다. 더욱 바람직하게는 회화나무 열매를 80%(v/v)의 에탄올의 용매로 상온에서 10 내지 24시간 추출한 조성물일 수 있다.The cosmetic composition for preventing skin aging or improving skin wrinkles may be a composition extracted from a tree fruit of 75 to 85% (v / v) of ethanol for 10 to 24 hours at room temperature. More preferably, the extract may be a composition extracted 10 to 24 hours at room temperature with a solvent of 80% (v / v) ethanol.
한편, 상기와 같은 피부 노화 방지용 화장료 조성물 또는 피부 주름 개선용 화장료 조성물은 피부 노화 방지용 화장품 또는 피부 주름 개선용 화장품 등의 제형으로 제공될 수 있다. 상술한 화장품의 제형으로는 유연 및 영양화장수, 영양크림, 마사지크림, 에센스, 파운데이션, 팩, 비누, 클렌징 폼, 클렌징 로션, 클렌징 크림, 바디로션, 및 바디크림으로 구성된 군으로부터 선택되는 어느 하나의 제형일 수 있으나, 상술한 예에 국한되지 않는다.On the other hand, the skin anti-aging cosmetic composition or cosmetic composition for improving skin wrinkles may be provided in a formulation such as skin anti-aging cosmetics or cosmetics for improving skin wrinkles. Formulations of the above-mentioned cosmetics include any one selected from the group consisting of soft and nourishing cream, nourishing cream, massage cream, essence, foundation, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body lotion, and body cream It may be a formulation, but is not limited to the examples described above.
상기와 같은 회화나무 추출물을 유효 성분으로 포함하는 화장료 조성물의 제형들을 제조함에 있어서, 통상적으로 함유되는 피부 외용제 조성물 100 중량부에 본 발명의 회화나무 추출물 0.001 내지 30 중량부, 바람직하게는 0.01 내지 10 중량부를 첨가할 수 있다. 한편, 상술한 화장료 조성물의 제형에는 본 발명의 회화 나무 추출물에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온 봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한, 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.In preparing the formulations of the cosmetic composition comprising the extract as an active ingredient as an active ingredient, 0.001 to 30 parts by weight, preferably 0.01 to 10 parts by weight of the extract of the invention of the present invention in 100 parts by weight of the external preparation composition for skin Parts by weight may be added. On the other hand, in the formulation of the cosmetic composition described above, in addition to the extract of the tree of the present invention, fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances For surfactants, water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or skin It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients commonly used in external preparations. In addition, the ingredients may be introduced in amounts generally used in the field of dermatology.
본 발명의 회화나무 추출물을 유효 성분으로 포함하는 조성물은 에스트로겐 분비를 촉진하여, 종래의 호르몬 요법에 사용되는 에스트로겐 제제 중 에스트라디올보다 체내 에스트로겐 분비 촉진 효과가 뛰어나며, 동시에 콜라게네이즈 활성을 저해하여, 폐경기 질환을 치료 또는 예방과 동시에, 피부 노화 방지 또는 피부 주름을 개선하는 용도로 유용하게 사용될 수 있다.The composition comprising the cedar extract of the present invention as an active ingredient promotes estrogen secretion, has a better effect of promoting estrogen secretion in the body than estradiol among estrogen preparations used in conventional hormone therapy, and simultaneously inhibits collagenase activity, In addition to treating or preventing menopausal diseases, it may be usefully used for the purpose of preventing skin aging or improving skin wrinkles.
이하, 본 발명의 구체적인 실시예를 통하여 발명의 구성 및 효과를 보다 상세히 설명하기로 한다. 그러나 하기의 실시예는 발명을 보다 명확하게 이해시키기 위한 것일 뿐이며, 발명의 권리범위가 하기 실시예에 한정되는 것은 아니다. 이하 본 발명의 실시예를 통해 본 발명을 상세히 설명한다.Hereinafter, the configuration and effect of the present invention through the specific embodiments of the present invention will be described in more detail. However, the following examples are only intended to more clearly understand the invention, the scope of the invention is not limited to the following examples. Hereinafter, the present invention will be described in detail through examples of the present invention.
[[ 실험예Experimental Example ]]
1. 회화나무 열매 추출물의 에스트로겐 분비 활성 효과 실험1. Experimental Effect of Estrogen Secretion Activity of Panax Fruit Extract
본 발명의 회화나무 열매 추출물이 에스트로겐 분비에 효과적인지 실험하기 위해, 표지 유전자가 결합된 에스트로겐 반응 서열을 포함하는 형질 전환된 세포주를 제작하였고, 그 세포주에 시료를 처리하여 표지 유전자의 발현을 측정하는 방법을 사용하였다.In order to test whether the extract of the present invention is effective for estrogen secretion, a transformed cell line comprising an estrogen response sequence to which a labeled gene is bound was prepared, and the sample was treated to measure the expression of the labeled gene. Method was used.
상기 시료의 특정 물질이 에스트로겐 반응 서열과 결합하여 특정 단백질의 전사가 활발히 이루어지면, 표지 유전자의 발현도 증가할 것이기 때문에, 시료 처리 후 일정 시간이 지난 뒤, 발현된 표지 유전자의 양을 측정하면, 시료가 에스트로겐 반응 서열에 얼마나 작용하였는지를 알 수 있게 된다. 구체적인 실험 준비 및 결과는 하기와 같다.If the specific substance of the sample is bound to the estrogen reaction sequence and the transcription of the specific protein is actively performed, the expression of the marker gene will also increase, so after a certain time after the sample processing, the amount of the expressed marker gene is measured, It can be seen how the sample has acted on the estrogen response sequence. Specific experimental preparations and results are as follows.
1-1) 세포주 준비1-1) Cell Line Preparation
유전자 재조합 방법을 이용하여 루시퍼라제(luciferase) 발현이 각각의 시스엘리먼트(cis-element)에 의해 조절 받는 유전자를 벡터 내에 제작하였다.Gene recombination methods were used to construct genes in which luciferase expression is regulated by each cis-element in a vector.
이와 같이 마련된 에스트로겐 반응 인자-루시퍼라제 벡터(Estrogen Responsive element-Luciferase vector(pcDNA))를 리포펙타민(lipopectamine)을 이용하여 유방 세포주인 MCF-7세포에 형질 전환(transfection)시킨 후, 항생제(G418)를 이용하여 콜로니(colony)를 선별하고, 이 세포주에 에스트라디올을 처리한 다음, 대조군과 비교하여 가장 큰 루시퍼라제 활성을 보이는 콜로니를 선별하여 실험 에 이용하였다.Estrogen Responsive Element-Luciferase Vector (pcDNA) prepared as described above was transfected into MCF-7 cells, which are breast cell lines using lipopectamine, and then antibiotics (G418). ) Colonies were selected, treated with estradiol, and colonies showing the greatest luciferase activity compared to the control group were used for the experiment.
1-2) 식물 추출물 준비1-2) Plant Extract Preparation
1-2-1) 회화나무 열매(1-2-1) Painting Tree Fruit 괴각Eccentric ) 추출물의 준비Preparation of Extract
중국산 회화나무 열매(학명 Sophora japonica L.) 1kg을 60메쉬로 균일하게 분쇄한 후, 상기 회화나무 열매 중량의 5배에 해당하는 80%(v/v) 주정을 가하여 상온에서 12시간 동안 추출하였다. 추출액을 여과포로 여과한 후, 여액을 원심분리시켜 침천물을 제거시킨 다음, 감압 농축하여 동결 건조시켰다.After crushing 1 kg of Chinese painting tree fruit (Sophora japonica L.) uniformly into 60 mesh, 80% (v / v) alcohol corresponding to 5 times the weight of the painting tree fruit was added and extracted at room temperature for 12 hours. . After the extract was filtered with a filter cloth, the filtrate was centrifuged to remove the precipitate, and then concentrated under reduced pressure and lyophilized.
1-2-2) 1-2-2) 감국Country 추출물의 준비 Preparation of Extract
한국산 건조 감국(학명 Chrysanthemum indicum L.) 전초를 시료양 중량 대비 5~10배에 해당하는 정제수에 넣어 활성물질이 용출될 수 있도록 70℃ 이상에서 2시간 동안 열탕 추출한 후, 추출액을 여과포로 여과한 다음에 여액을 원심분리시켜 침전물을 제거하였다. 분리된 추출물은 감압 농축하여 동결 건조시켰다.After putting dried Korean ginseng (Chrysanthemum indicum L.) outpost into purified water corresponding to 5 ~ 10 times the weight of the sample, hot water was extracted at 70 ℃ for 2 hours so that the active substance could be eluted, and then the extract was filtered with a filter cloth. The filtrate was centrifuged to remove the precipitate. The separated extract was concentrated under reduced pressure and freeze dried.
1-2-3) 산수유 추출물의 준비1-2-3) Preparation of Cornus Extract
한국산 건조 산수유(학명 Cornus officinalis Siebold et Zucc) 열매를 시료양 중량 대비 5~10배에 해당하는 정제수에 넣어 활성물질이 용출될 수 있도록 70℃ 이상에서 2시간 동안 열탕 추출한 후, 추출액을 여과포로 여과한 다음에 여액을 원심분리시켜 침전물을 제거하였다. 분리된 추출물은 감압 농축하여 동결 건조시켰다.After drying dried cornus (Korean Cornus officinalis Siebold et Zucc) fruit from Korea in purified water equivalent to 5-10 times the weight of the sample, the hot water was extracted for 2 hours at 70 ℃ or higher to elute the active substance, and the extract was filtered with a filter cloth. The filtrate was then centrifuged to remove the precipitate. The separated extract was concentrated under reduced pressure and freeze dried.
2-1) 세포주에 식물 추출물 투여 및 2-1) administering plant extracts to cell lines and 루시퍼라제Luciferase 활성 측정 Active measurement
96-well plate에 표지 유전자를 발현시킨 상기 세포주를 5x103 cell/100㎕로 분주하고, 24시간 동안 음성대조군(Dimethyl sulfoxide;DMSO 99% 0.5㎕), 상기 각각의 식물 추출물, 양성 대조군(에스트라디올; Estradiol)을 처리한 후, PBS 완충용액으로 두번 씻어 내고, 용해 완충 용액(Lysis buffer : 20mM-Tris, 150mM NaCl, 1% TX-100, 2mM DTT)를 96-well의 각 well에 50㎕ 첨가하여, 세포 lysate를 제작하였다.Dispense the cell line expressing the labeling gene in a 96-well plate with 5 × 10 3 cells / 100 μl and negative control group (Dimethyl sulfoxide; DMSO 99% 0.5 μl), the respective plant extracts, the positive control group (estradiol) Estradiol), washed twice with PBS buffer, and 50 μl of lysis buffer (Lysis buffer: 20 mM-Tris, 150 mM NaCl, 1% TX-100, 2 mM DTT) was added to each well of 96-well. Thus, cell lysate was produced.
4℃에서 multi-vortex로 30분간 혼합(vortexing)시켜 준 후, 5㎕씩 취해서 클리니플레이트(cliniplate)에 옮기고 루시페린(luciferin)을 25㎕ 첨가하여 루미노미터(luminometer)로 루시퍼라제 활성을 측정하였다.After 30 minutes of vortexing at 4 ° C. with a multi-vortex, 5 μl of each was transferred to a clinplate, and 25 μl of luciferin was added to measure luciferase activity using a luminometer. It was.
발현된 루시퍼라제 양에 따라, 에스트로겐 반응 인자의 발현 정도를 알 수 있었다. 그 결과를 하기 표1과 도1에 나타내었다.According to the amount of luciferase expressed, the expression level of the estrogen response factor was known. The results are shown in Table 1 and FIG.
(Relative Light Unit)RLU
(Relative Light Unit)
(fold)Drainage
(fold)
상기 표1에서 알 수 있듯이 괴각 추출물(회화나무 열매 추출물)은 음성 대조구인 DMSO(디메틸설폭사이드)에 비해 5배 이상 에스트로겐 반응 활성을 보이며, 에스트라디올에 비해서도 우수함을 알 수 있었다. 따라서 본 발명에 따른 회화나무 열매 추출물은 에스트로겐 대체 천연 물질로서 작용하여, 갱년기 장애나 노화 등 에스트로겐 분비 감소로 인한 각종 질환 개선 및 치료에 유용하게 적용될 수 있을 것으로 예상된다. As can be seen in Table 1, the worm extract (Panax fruit extract) showed more than five times the estrogen reaction activity compared to DMSO (dimethyl sulfoxide), a negative control, it was found that even compared to estradiol. Therefore, it is expected that the extract according to the present invention acts as a natural substitute for estrogen, and can be usefully applied to improve and treat various diseases caused by decreased estrogen secretion such as menopausal disorder or aging.
2. 2. 콜라게네이즈Collagenase 활성 억제 효능 평가 실험 Activity inhibitory effect evaluation experiment
회화나무 열매 추출물(괴각 추출물) 0.1ml에 아조콜 콜라겐(Sigma) 1mg과 콜라게네이즈 효소(Sigma) 9.4unit를 첨가하고 총 부피 1ml가 되게 하고 43℃에서 1시간 반응시킨 다음, 3,000rpm에서 10분간 원심 분리시켜 상등액을 취한 다음에 550nm에서 흡광도 측정하였다. 그 결과는 하기 표2 및 도 2에 나타난 바와 같다.1mg of azocol collagen (Sigma) and 9.4units of collagenase enzyme (Sigma) were added to 0.1ml of the extract of the locust fruit, and the total volume was 1ml, and the reaction was carried out at 43 ° C for 1 hour, followed by 10 at 3,000rpm. The supernatant was collected by centrifugation for a minute and then the absorbance was measured at 550 nm. The results are as shown in Table 2 and FIG.
실험군
Experimental group
상기 표2의 결과로부터, 괴각(회화나무 열매) 추출물은 콜라겐 분해 효소 활성 억제 효능이 있음을 알 수 있다. From the results of Table 2, it can be seen that the wormwood (Pear Tree Fruit) extract has an effect of inhibiting collagen degrading enzyme activity.
3. 에스트로겐 분비 효능 동물 실험 (3. Estrogen Secretion Efficacy in Animal Experiment InIn vivovivo ))
상기 실험예 1에서 제조한 괴각 추출물, 감국 추출물, 산수유 추출물을 하기 표3의 조성으로 2000mg 정제 형태로 제조하였다.The lump extract, persimmon extract, and cornus extract prepared in Experimental Example 1 were prepared in a 2000 mg tablet form with the composition of Table 3 below.
(wt%)Nerd extract
(wt%)
(wt%)Persimmon Extract
(wt%)
(wt%)Cornus Extract
(wt%)
(wt%)Xylitol
(wt%)
(wt%)Zinc oxide
(wt%)
(wt%)Vitamin c
(wt%)
(wt%)Vitamin B2
(wt%)
(wt%)Dry yeast selenium
(wt%)
(wt%)Tea powder
(wt%)
(wt%)Chicory White
(wt%)
실
시
예
room
city
Yes
생후 21일된 미성숙 Sprague-Dawley 암컷 흰쥐를 군당 5마리로 나누어 상기 조성물을 각각 200mg/kg 용량으로 3일간 경구 투여한 후, 효소 면역 반응(EIA)을 이용하여 혈액 내 에스트라디올의 농도를 측정하였다.The 21-day-old immature Sprague-Dawley female rats were divided into 5 rats per group, and the compositions were orally administered at 200 mg / kg doses for 3 days.
상기 표 4의 결과로부터, 본 발명의 조성물은 에스트라디올 분비 촉진 효능이 있음을 알 수 있다.From the results of Table 4, it can be seen that the composition of the present invention has an estradiol secretion promoting effect.
4. 갱년기 증상 여성에 의한 폐경기 증상 개선 효능 평가4. Evaluation of menopausal symptoms improvement efficacy by women
갱년기 증상이 있는 평균 연령 48세 여성 30명을 대상으로 10명씩 나누어 상기 실시예 3, 5와 비교예의 정제를 1일 2회, 1회 1캅셀씩 8주간 복용하고, 안면 홍조, 피로감, 불면증, 우울증 개선 여부에 대해 평가하였다.30 women aged 48 years old with menopausal symptoms were divided into 10 people and taken the tablets of Examples 3 and 5 twice a day, once a capsule once a week for 8 weeks, hot flashes, fatigue, insomnia, We evaluated whether depression was improved.
평가 척도Rating scale
0점 : 효과 없음 0 points: no effect
1점 : 조금 효과가 있음1 point: slightly effective
2점 : 효과가 있음2 points: Effective
3점 : 효과가 뛰어남3 points: excellent effect
상기 표5의 결과로부터, 본 발명의 회화나무 추출물을 유효성분으로 포함하는 조성물은 여성 갱년기 증상 개선에 효과가 있음을 알 수 있다.From the results in Table 5, it can be seen that the composition containing the extract of the present invention as an active ingredient is effective in improving female menopausal symptoms.
한편, 하기에는 본 발명의 회화나무 추출물을 이용한 제형의 예를 기재하였으나, 본 발명의 제제가 하기에 국한되는 것은 아니다. On the other hand, the following describes an example of the formulation using the painting tree extract of the present invention, the formulation of the present invention is not limited thereto.
[[ 제조예Production Example : 회화나무 추출물을 이용한 제제] : Formulation Using Painting Tree Extract]
제조예Production Example 1. One. 산제의Powder 제조 Produce
회화나무 추출물 분말 20 mg
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조하였다. The above ingredients were mixed and filled in an airtight cloth to prepare a powder.
제조예Production Example 2. 정제의 제조 2. Preparation of Tablets
회화나무 추출물 분말 10 mg
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg 2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다. After mixing the above components was prepared by tableting according to the conventional manufacturing method of the tablet.
제조예Production Example 3. 캡슐제의 제조 3. Preparation of Capsule
회화나무 추출물 분말 10 mg
결정성 셀룰로오스 3 mg 3 mg of crystalline cellulose
락토오스 14.8 mg Lactose 14.8 mg
마그네슘 스테아레이트 0.2 mg Magnesium Stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다. According to a conventional capsule preparation method, the above ingredients were mixed and filled into gelatin capsules to prepare capsules.
제조예Production Example 4. 4. 액제의Liquid 제조 Produce
회화나무 추출물 분말 20 mg
이성화당 10 g 10 g of isomerized sugar
만니톨 5 g 5 g of mannitol
정제수 적량 Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조하였다. After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution was prepared by sterilization.
제조예Production Example 5. 건강 식품의 제조 5. Manufacture of Healthy Foods
회화나무 추출물 분말 1000 ㎎ Panax Extract Powder 1000mg
비타민 혼합물 적량 Vitamin mixture proper amount
비타민 A 아세테이트 70 ㎍ 70 μg of Vitamin A Acetate
비타민 E 1.0 ㎎ Vitamin E 1.0 mg
비타민 B1 0.13 ㎎ Vitamin B1 0.13 mg
비타민 B2 0.15 ㎎ Vitamin B2 0.15 mg
비타민 B6 0.5 ㎎ Vitamin B6 0.5 mg
비타민 B12 0.2 ㎍ 0.2 μg of vitamin B12
비타민 C 10 ㎎
비오틴 10 ㎍ 10 μg biotin
니코틴산아미드 1.7 ㎎ Nicotinic Acid 1.7 mg
엽산 50 ㎍ Folate 50 ㎍
판토텐산 칼슘 0.5 ㎎ Calcium Pantothenate 0.5mg
무기질 혼합물 적량 Mineral mixture
황산제1철 1.75 ㎎ Ferrous Sulfate 1.75 mg
산화아연 0.82 ㎎ Zinc Oxide 0.82 mg
탄산마그네슘 25.3 ㎎ Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎ Potassium monophosphate 15 mg
제2인산칼슘 55 ㎎ Dibasic calcium phosphate 55 mg
구연산칼륨 90 ㎎ Potassium Citrate 90 mg
탄산칼슘 100 ㎎
염화마그네슘 24.8 ㎎ Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제조예Production Example 6. 유연 및 영양화장수의 제조 6. Preparation of Softening and Nutritious Cosmetics
회화나무 추출물 분말 100.0 mgPanax Extract Powder 100.0 mg
1, 3-부틸렌글리콜 10.0 mg1, 3-butylene glycol 10.0 mg
디소듐이디티에이 0.5 mgDisodium IDT 0.5 mg
알란토인 1.0 mgAllantoin 1.0 mg
디포타슘글리시리제이트 0.5 mgDipotassium glycylizate 0.5 mg
구연산 0.1 mgCitric acid0.1 mg
소륨시트레이트 0.2 mgSodium citrate 0.2 mg
글리세레스-26 10.0 mgGlyceres-26 10.0 mg
알부틴 20.0 mgArbutin 20.0 mg
하이드로제네이티드캐스터 오일 10.0 mgHydrogenated Castor Oil 10.0 mg
에탄올 300.0 mgEthanol 300.0 mg
보존제 미량Preservative Trace
착색제 미량Trace amount of colorant
착향제 미량Trace amount of flavor
정제수 500 mg500 mg of purified water
제조예Production Example 7. 영양크림의 제조 7. Preparation of nutritional cream
회화나무 열매 추출물 100.0 mgPassionfruit Extract 100.0 mg
1, 3-부틸렌 글리콜 70.0 mg1, 3-butylene glycol 70.0 mg
글리세린 10.0 mgGlycerin 10.0 mg
D-판테놀 1.0 mgD-panthenol 1.0 mg
마그네슘알루미늄실리케이트 3 mgMagnesium Aluminum Silicate 3 mg
호호바 오일 50mgJojoba oil 50mg
유동 파라핀 70mgLiquid Paraffin 70mg
스쿠알란 30mgSqualane 30mg
트리에탄올아민 3mgTriethanolamine 3mg
도 1은 양성대조군(에스트라디올)과 본 발명의 괴각추출물의 농도별 에스토로겐 분비 촉진 실험결과를 비교하여 나타낸 그래프이다.1 is a graph showing a comparison of the results of the estrogen secretion promoting experiments according to the concentration of the positive control group (estradiol) and the present invention.
도 2는 본 발명의 일실시예에 따른 괴각추출물의 콜라게네이즈 활성 저해 효능을 독시사이클린과 비교하여 나타낸 그래프이다.Figure 2 is a graph showing the collagenase activity inhibitory effect of the lump extract according to an embodiment of the present invention compared to doxycycline.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090062112A KR20110004603A (en) | 2009-07-08 | 2009-07-08 | Cauliflower extract for treating or preventing menopausal diseases, preventing skin aging, or improving skin wrinkles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090062112A KR20110004603A (en) | 2009-07-08 | 2009-07-08 | Cauliflower extract for treating or preventing menopausal diseases, preventing skin aging, or improving skin wrinkles |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20110004603A true KR20110004603A (en) | 2011-01-14 |
Family
ID=43612045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090062112A Withdrawn KR20110004603A (en) | 2009-07-08 | 2009-07-08 | Cauliflower extract for treating or preventing menopausal diseases, preventing skin aging, or improving skin wrinkles |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20110004603A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018087175A (en) * | 2016-11-30 | 2018-06-07 | 花王株式会社 | Muscle atrophy inhibitor |
KR20190077722A (en) * | 2017-12-26 | 2019-07-04 | 주식회사 단정바이오 | Cosmetic composition comprising the extract of fermented Sophora Japonica Fruits for skin anti-wrinkle effect and producing method thereof |
EP3628177A1 (en) | 2018-09-28 | 2020-04-01 | Amorepacific Corporation | Liquid food composition comprising sophora japonica extract |
KR20210085672A (en) | 2019-12-31 | 2021-07-08 | (주)뷰티나인 | Hub complex composition |
WO2021137587A1 (en) * | 2019-12-31 | 2021-07-08 | Beauty9, Inc. | Composition for improving or preventing menopausal symptoms, including vitex agunus-castus extract as active ingredient |
KR20210086854A (en) | 2019-12-31 | 2021-07-09 | (주)뷰티나인 | Hub complex composition |
KR20210086851A (en) | 2019-12-31 | 2021-07-09 | (주)뷰티나인 | Natural plant composition containing probiotics |
KR20210104596A (en) * | 2020-02-17 | 2021-08-25 | (주)에이스바이옴 | Composition comprising Lactobacillus gasseri BNR17 for alleviating a menopausal disorder |
KR20210108264A (en) | 2020-02-25 | 2021-09-02 | (주)아모레퍼시픽 | Liquid food composition effectively dispersing insoluble component with dietary fiber |
KR20220033155A (en) | 2020-09-09 | 2022-03-16 | (주)뷰티나인 | Hub complex composition |
US11882954B2 (en) | 2019-06-19 | 2024-01-30 | Youngsil YU | Flower arrangement support system |
-
2009
- 2009-07-08 KR KR1020090062112A patent/KR20110004603A/en not_active Withdrawn
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018087175A (en) * | 2016-11-30 | 2018-06-07 | 花王株式会社 | Muscle atrophy inhibitor |
KR20190077722A (en) * | 2017-12-26 | 2019-07-04 | 주식회사 단정바이오 | Cosmetic composition comprising the extract of fermented Sophora Japonica Fruits for skin anti-wrinkle effect and producing method thereof |
US11154078B2 (en) | 2018-09-28 | 2021-10-26 | Amorepacific Corporation | Liquid food composition comprising Sophora japonica extract |
EP3628177A1 (en) | 2018-09-28 | 2020-04-01 | Amorepacific Corporation | Liquid food composition comprising sophora japonica extract |
KR20200036521A (en) | 2018-09-28 | 2020-04-07 | (주)아모레퍼시픽 | Liquid food composition comprising extracts from sophora japonica |
US11882954B2 (en) | 2019-06-19 | 2024-01-30 | Youngsil YU | Flower arrangement support system |
KR20210085672A (en) | 2019-12-31 | 2021-07-08 | (주)뷰티나인 | Hub complex composition |
WO2021137587A1 (en) * | 2019-12-31 | 2021-07-08 | Beauty9, Inc. | Composition for improving or preventing menopausal symptoms, including vitex agunus-castus extract as active ingredient |
KR20210086854A (en) | 2019-12-31 | 2021-07-09 | (주)뷰티나인 | Hub complex composition |
KR20210086851A (en) | 2019-12-31 | 2021-07-09 | (주)뷰티나인 | Natural plant composition containing probiotics |
KR20210104596A (en) * | 2020-02-17 | 2021-08-25 | (주)에이스바이옴 | Composition comprising Lactobacillus gasseri BNR17 for alleviating a menopausal disorder |
CN115087453A (en) * | 2020-02-17 | 2022-09-20 | 株式会社艾希柏恩 | Composition comprising lactobacillus gasseri BNR17 for the treatment of climacteric disorders |
US20230124145A1 (en) * | 2020-02-17 | 2023-04-20 | Acebiome Inc. | Composition for treating climacteric disorder comprising lactobacillus gasseri bnr17 |
KR20230109598A (en) * | 2020-02-17 | 2023-07-20 | (주)에이스바이옴 | Composition comprising Lactobacillus gasseri BNR17 for alleviating a menopausal disorder |
WO2021167350A1 (en) * | 2020-02-17 | 2021-08-26 | (주)에이스바이옴 | Composition for treating climacteric disorder comprising lactobacillus gasseri bnr17 |
AU2021224434B2 (en) * | 2020-02-17 | 2024-10-10 | Acebiome Inc. | Composition for treating climacteric disorder comprising Lactobacillus gasseri BNR17 |
KR20210108264A (en) | 2020-02-25 | 2021-09-02 | (주)아모레퍼시픽 | Liquid food composition effectively dispersing insoluble component with dietary fiber |
KR20220033155A (en) | 2020-09-09 | 2022-03-16 | (주)뷰티나인 | Hub complex composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110004603A (en) | Cauliflower extract for treating or preventing menopausal diseases, preventing skin aging, or improving skin wrinkles | |
KR101855094B1 (en) | Composition for improving skin wrinkle and enhancing elasticity | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
KR102065934B1 (en) | Composition for prevention and treatment of climacteric disorder comprising extracts of Dendropanax morbifera and Rhynchosia Nulubilis | |
WO2007133054A1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
KR102204346B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
KR102201312B1 (en) | Pharmaceutical Composition Comprising Extracts of Ginseng and Ginseng Berry for Preventing or Treating Muscle Disease | |
KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR20160114841A (en) | Composition for improvement or treatment of Fat comprising Eucommiae ulmoides Oliv. Bark. extract or Adiponectin isolated therefrom as active ingredient | |
KR20070113330A (en) | External skin composition comprising gompi extract | |
KR100921971B1 (en) | Composition containing blooming sally extract as an active ingredient | |
US10806766B2 (en) | Method for treating, preventing, or alleviating osteoporosis | |
KR102073016B1 (en) | Composition Comprising Red Ginseng Extract and Brassica oleracea Extract for Preventing or Treating Climacteric Syndrome | |
KR20200117957A (en) | A composition for preventing or treating atopic dermatitis comprising the extract of corn silk | |
KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR20150039342A (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
EP3449736B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
JP6753600B2 (en) | Absorption enhancer | |
KR20140087779A (en) | Antiobestic composition comprising rosa laevigata extract | |
KR20210013497A (en) | A composition for preventing or treating atopic dermatitis comprising the extract of oat sprout | |
HK1246095A1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
KR20220046737A (en) | A composition for anti-inflammation activity comprising Chrysanthemum zawadskii leaf and stem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20090708 |
|
PG1501 | Laying open of application | ||
PC1203 | Withdrawal of no request for examination | ||
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |